Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.64
+$0.13 · +5.18%
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Previous close
$2.64
+$0.13 · +5.18%
Regular session · ET · Market data may be delayed.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Day range
Current $2.64
52-week range
Current $2.64
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
27
Expensive
Sentiment
70
Bullish
Risk
67
High Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Day range
Current $2.64
52-week range
Current $2.64
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 67.43M USD | — | — | — |
| Gross profit | — | 67.43M USD | — | — | — |
| Research and development | 107.3M USD | 167.77M USD | 235.16M USD | 172.73M USD | 175.6M USD |
| Selling, general, and administrative | 37.72M USD | 87.12M USD | 59.4M USD | 54.55M USD | 40.94M USD |
| Operating expenses | 152.81M USD | 258.62M USD | 299.51M USD | 227.29M USD | 216.54M USD |
| Interest income | — | — | — | 2.26K USD | — |
| Interest expense | — | — | — | 2.58M USD | — |
| Depreciation and amortization | 739K USD | 1.29M USD | 1.39M USD | 1.43M USD | 544K USD |
| Operating income | −152.81M USD | −191.19M USD | −299.51M USD | −227.29M USD | −216.54M USD |
| Net income | −137.06M USD | −165.84M USD | −292.19M USD | −236.81M USD | −158.73M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.67
190.53% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.74M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3.35M0.00%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2.17M0.00%95.4B USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM1.51M0.02%6.41B USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO1.08M0.01%18B USD0.06%$112.66+0.50%
Vanguard Health Care ETFVHT840.25K0.00%22B USD0.09%$319.01+1.64%
Federated Hermes MDT Small Cap Core ETFFSCC694.41K0.16%424.12M USD0.50%$34.00+0.53%
Dimensional - US Small Cap ETFDFAS617.8K0.00%33.87B USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTFederated Hermes MDT Small Cap Core ETFFSCCDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
